Focusing on preventing antigen escape in MM following CAR T cell therapy, Zah et al. designed and evaluated 10 single-chain bispecific BCMA/CS1 (OR-gate) CAR T cells to combine uniform CS1 expression and potent antitumor BCMA efficacy. Several BCMA/CS1 CAR T cell designs had superior expression, function, and manufacturability, and in vivo, prevented antigen escape compared to T cells that co-expressed individual BCMA and CS1 (Dual) CARs. Combination with anti-PD-1 increased initial antitumor efficacy, but relapsed at later time points, suggesting anti-PD-1 mediated exhaustion in the absence of antigen.
Contributed by Katherine Turner
(1) Zah E (2) Nam E (3) Bhuvan V (4) Tran U (5) Ji BY (6) Gosliner SB (7) Wang X (8) Brown CE (9) Chen YY
Focusing on preventing antigen escape in MM following CAR T cell therapy, Zah et al. designed and evaluated 10 single-chain bispecific BCMA/CS1 (OR-gate) CAR T cells to combine uniform CS1 expression and potent antitumor BCMA efficacy. Several BCMA/CS1 CAR T cell designs had superior expression, function, and manufacturability, and in vivo, prevented antigen escape compared to T cells that co-expressed individual BCMA and CS1 (Dual) CARs. Combination with anti-PD-1 increased initial antitumor efficacy, but relapsed at later time points, suggesting anti-PD-1 mediated exhaustion in the absence of antigen.
Contributed by Katherine Turner
ABSTRACT: Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse exists. Here we report the rational design and optimization of bispecific CAR-T cells with robust activity against heterogeneous multiple myeloma (MM) that is resistant to conventional CAR-T cell therapy targeting B-cell maturation antigen (BCMA). We demonstrate that BCMA/CS1 bispecific CAR-T cells exhibit superior CAR expression and function compared to T cells that co-express individual BCMA and CS1 CARs. Combination therapy with anti-PD-1 antibody further accelerates the rate of initial tumor clearance in vivo, while CAR-T cell treatment alone achieves durable tumor-free survival even upon tumor re-challenge. Taken together, the BCMA/CS1 bispecific CAR presents a promising treatment approach to prevent antigen escape in CAR-T cell therapy against MM, and the vertically integrated optimization process can be used to develop robust cell-based therapy against novel disease targets.
Author Info:
(1) Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. Amgen, Thousand Oaks, CA, USA. (2)
Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. (3) Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. (4) Department of Chemistry and Biochemistry, University of California-Los Angeles, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. (5) Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. (6) Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. (7) Department of Hematology and Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory, City of Hope Beckman Research Institute and Medical Center, 1500 E. Duarte Rd., Duarte, CA, USA. (8) Department of Hematology and Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory, City of Hope Beckman Research Institute and Medical Center, 1500 E. Duarte Rd., Duarte, CA, USA. (9) Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. yvonne.chen@ucla.edu. Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. yvonne.chen@ucla.edu. Parker Institute for Cancer Immunotherapy Center at UCLA, 420 Westwood Plaza, BH 5513, Los Angeles, CA, USA. yvonne.chen@ucla.edu.
Citation: Nat Commun 2020 May 8 11:2283 Epub05/08/2020
